Search details
1.
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Cell
; 185(16): 2918-2935.e29, 2022 08 04.
Article
in English
| MEDLINE | ID: mdl-35803260
2.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 23(2): 279-291, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35033226
3.
A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases.
Adv Radiat Oncol
; 9(4): 101411, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38406391
4.
Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors.
Adv Radiat Oncol
; 7(2): 100880, 2022.
Article
in English
| MEDLINE | ID: mdl-35097241
5.
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
JAMA Otolaryngol Head Neck Surg
; 148(3): 268-276, 2022 Mar 01.
Article
in English
| MEDLINE | ID: mdl-35050348
6.
Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
Int J Radiat Oncol Biol Phys
; 114(4): 666-675, 2022 11 15.
Article
in English
| MEDLINE | ID: mdl-35643252
7.
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers.
Head Neck
; 44(6): 1442-1452, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35355358
Results
1 -
7
de 7
1
Next >
>>